MYOK News and Press, MyoKardia Inc. From 06/19/20

-- MyoKardia to Host Conference Call at 8:30 a.m. ET on Monday, June 22, 2020 -- BRISBANE, Calif., June 19, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that data from the company’s Phase 2a multiple-ascending dose study of danicamtiv (formerly MYK-491...

BRISBANE, Calif., June 16, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that Tassos Gianakakos, Chief Executive Officer, will participate in a fireside chat at the virtual BMO 2020 Prescriptions for Success Healthcare Conference on Tuesday, June 23 rd , 2020 at 10...

Shares of MyoKardia (NASDAQ: MYOK) climbed 62.8% in May, according to data provided by S&P Global Market Intelligence , after the company said its investigational heart drug met primary and secondary endpoints in a phase 3 clinical trial. Image source: Getty Images. Mavacamten is...

MyoKardia (NASDAQ: MYOK) soared 96% this week after reporting its investigational heart drug met primary and all secondary endpoints in a phase 3 clinical trial. The clinical stage biotech company will submit mavacamten for the treatment of obstructive hypertrophic cardiomyopathy (HCM) ...

Myriad Receives the FDA Approval for Testing Ovarian Cancer Myriad Genetics ( MYGN ) announced that the FDA has given green signal to its myChoice CDx test to be used as a companion diagnostic for the identification of advanced ovarian cancer patients. The company stated that the device...

MyoKardia (NASDAQ: MYOK ) has priced its public offering of 5.25M common shares at $105.00/share. More news on: MyoKardia, Inc., Healthcare stocks news, , Stocks on the move, Read more ...

Gainers: Cellect Biotechnology (NASDAQ: APOP ) +77% . More news on: Cellect Biotechnology Ltd., MyoKardia, Inc., Remark Holdings, Inc., Stocks on the move, , Read more ...

MyoKardia (NASDAQ: MYOK) , a clinical-stage biotech, is having a tremendous Monday morning. The drugmaker's shares were up by an eye-popping 65% on sky-high volume as of 9:59 a.m. EDT on Monday.  The spark? Ahead of the opening bell, MyoKardia announced that its experimental obstructive...

Cellect Biotechnology (NASDAQ: APOP ) +126%  on publication of ApoGraft data ahead of clinical trial. More news on: Cellect Biotechnology Ltd., MyoKardia, Inc., AMC Entertainment Holdings, Inc., Stocks on the move, , Read more ...

MyoKardia (NASDAQ: MYOK ) announces positive results from a Phase 3 clinical trial, EXPLORER-HCM , evaluating lead drug mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), an inherited disorder characterized by abnormal thickening of heart muscle leadi...